Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Author Correction: The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation.

Smith L, Farzan R, Ali S, Buluwela L, T Saurin A, Meek DW.

Sci Rep. 2018 Mar 22;8(1):5237. doi: 10.1038/s41598-018-23384-5.

2.

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.

Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, Barbazanges M, Starkey R, Ottaviani S, Harrod A, Aboagye EO, Buluwela L, Fuchter MJ, Barrett AGM, Coombes RC, Ali S.

Mol Cancer Ther. 2018 Jun;17(6):1156-1166. doi: 10.1158/1535-7163.MCT-16-0847. Epub 2018 Mar 15.

PMID:
29545334
3.

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.

Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M.

Nat Commun. 2017 Nov 30;8(1):1865. doi: 10.1038/s41467-017-01864-y.

4.

The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation.

Smith L, Farzan R, Ali S, Buluwela L, Saurin AT, Meek DW.

Sci Rep. 2017 Nov 23;7(1):16115. doi: 10.1038/s41598-017-16394-2. Erratum in: Sci Rep. 2018 Mar 22;8(1):5237.

5.

p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.

Periyasamy M, Singh AK, Gemma C, Kranjec C, Farzan R, Leach DA, Navaratnam N, Pálinkás HL, Vértessy BG, Fenton TR, Doorbar J, Fuller-Pace F, Meek DW, Coombes RC, Buluwela L, Ali S.

Nucleic Acids Res. 2017 Nov 2;45(19):11056-11069. doi: 10.1093/nar/gkx721.

6.

Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.

Patel H, Abduljabbar R, Lai CF, Periyasamy M, Harrod A, Gemma C, Steel JH, Patel N, Busonero C, Jerjees D, Remenyi J, Smith S, Gomm JJ, Magnani L, Győrffy B, Jones LJ, Fuller-Pace F, Shousha S, Buluwela L, Rakha EA, Ellis IO, Coombes RC, Ali S.

Clin Cancer Res. 2016 Dec 1;22(23):5929-5938. Epub 2016 Jun 14.

7.

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.

Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF, Metodieva G, de Giorgio A, Williams RL, Santos DB, Gomez PJ, Lin ML, Metodiev MV, Stebbing J, Castellano L, Magnani L, Coombes RC, Buluwela L, Ali S.

Oncogene. 2017 Apr 20;36(16):2286-2296. doi: 10.1038/onc.2016.382. Epub 2016 Oct 17.

8.

Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.

Aleskandarany MA, Abduljabbar R, Ashankyty I, Elmouna A, Jerjees D, Ali S, Buluwela L, Diez-Rodriguez M, Caldas C, Green AR, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2016 Sep;159(2):215-27. doi: 10.1007/s10549-016-3934-5. Epub 2016 Aug 11.

9.

APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer.

Periyasamy M, Patel H, Lai CF, Nguyen VTM, Nevedomskaya E, Harrod A, Russell R, Remenyi J, Ochocka AM, Thomas RS, Fuller-Pace F, Győrffy B, Caldas C, Navaratnam N, Carroll JS, Zwart W, Coombes RC, Magnani L, Buluwela L, Ali S.

Cell Rep. 2015 Oct 6;13(1):108-121. doi: 10.1016/j.celrep.2015.08.066. Epub 2015 Sep 24.

10.

LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner.

Kramer HB, Lai CF, Patel H, Periyasamy M, Lin ML, Feller SM, Fuller-Pace FV, Meek DW, Ali S, Buluwela L.

Nucleic Acids Res. 2016 Jan 29;44(2):582-94. doi: 10.1093/nar/gkv948. Epub 2015 Sep 22.

11.

Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer.

Lin ML, Patel H, Remenyi J, Banerji CR, Lai CF, Periyasamy M, Lombardo Y, Busonero C, Ottaviani S, Passey A, Quinlan PR, Purdie CA, Jordan LB, Thompson AM, Finn RS, Rueda OM, Caldas C, Gil J, Coombes RC, Fuller-Pace FV, Teschendorff AE, Buluwela L, Ali S.

Oncotarget. 2015 Aug 28;6(25):21685-703.

12.

LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer.

Xu Y, Zhang H, Nguyen VT, Angelopoulos N, Nunes J, Reid A, Buluwela L, Magnani L, Stebbing J, Giamas G.

Cell Rep. 2015 Aug 4;12(5):837-49. doi: 10.1016/j.celrep.2015.06.073. Epub 2015 Jul 23.

13.

Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer.

Abduljabbar R, Al-Kaabi MM, Negm OH, Jerjees D, Muftah AA, Mukherjee A, Lai CF, Buluwela L, Ali S, Tighe PJ, Green A, Ellis I, Rakha E.

Breast Cancer Res Treat. 2015 Apr;150(3):511-22. doi: 10.1007/s10549-015-3348-9. Epub 2015 Mar 21.

PMID:
25794775
14.

Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer.

Abduljabbar R, Negm OH, Lai CF, Jerjees DA, Al-Kaabi M, Hamed MR, Tighe PJ, Buluwela L, Mukherjee A, Green AR, Ali S, Rakha EA, Ellis IO.

Breast Cancer Res Treat. 2015 Apr;150(2):335-46. doi: 10.1007/s10549-015-3335-1. Epub 2015 Mar 12.

PMID:
25762479
15.

Engineered repressors are potent inhibitors of androgen receptor activity.

Brooke GN, Powell SM, Lavery DN, Waxman J, Buluwela L, Ali S, Bevan CL.

Oncotarget. 2014 Feb 28;5(4):959-69.

16.

Prolonged exposure to bradykinin and prostaglandin E2 increases TRPV1 mRNA but does not alter TRPV1 and TRPV1b protein expression in cultured rat primary sensory neurons.

Mistry S, Paule CC, Varga A, Photiou A, Jenes A, Avelino A, Buluwela L, Nagy I.

Neurosci Lett. 2014 Apr 3;564:89-93. doi: 10.1016/j.neulet.2014.02.006. Epub 2014 Feb 11.

PMID:
24525250
17.

Anandamide produced by Ca(2+)-insensitive enzymes induces excitation in primary sensory neurons.

Varga A, Jenes A, Marczylo TH, Sousa-Valente J, Chen J, Austin J, Selvarajah S, Piscitelli F, Andreou AP, Taylor AH, Kyle F, Yaqoob M, Brain S, White JP, Csernoch L, Di Marzo V, Buluwela L, Nagy I.

Pflugers Arch. 2014 Jul;466(7):1421-35. doi: 10.1007/s00424-013-1360-7. Epub 2013 Oct 10.

18.

Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells.

Lai CF, Flach KD, Alexi X, Fox SP, Ottaviani S, Thiruchelvam PT, Kyle FJ, Thomas RS, Launchbury R, Hua H, Callaghan HB, Carroll JS, Charles Coombes R, Zwart W, Buluwela L, Ali S.

Nucleic Acids Res. 2013 Dec;41(22):10228-40. doi: 10.1093/nar/gkt827. Epub 2013 Sep 17.

19.

Characterisation of the androgen regulation of glycine N-methyltransferase in prostate cancer cells.

Ottaviani S, Brooke GN, O'Hanlon-Brown C, Waxman J, Ali S, Buluwela L.

J Mol Endocrinol. 2013 Nov 7;51(3):301-12. doi: 10.1530/JME-13-0169. Print 2013 Dec.

20.

miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts.

Pellegrino L, Stebbing J, Braga VM, Frampton AE, Jacob J, Buluwela L, Jiao LR, Periyasamy M, Madsen CD, Caley MP, Ottaviani S, Roca-Alonso L, El-Bahrawy M, Coombes RC, Krell J, Castellano L.

Nucleic Acids Res. 2013 May 1;41(10):5400-12. doi: 10.1093/nar/gkt245. Epub 2013 Apr 10.

21.

Discovery of a new class of liver receptor homolog-1 (LRH-1) antagonists: virtual screening, synthesis and biological evaluation.

Rey J, Hu H, Kyle F, Lai CF, Buluwela L, Coombes RC, Ortlund EA, Ali S, Snyder JP, Barrett AG.

ChemMedChem. 2012 Nov;7(11):1909-14. doi: 10.1002/cmdc.201200307. Epub 2012 Sep 7.

PMID:
22961990
22.

Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.

Baud MG, Leiser T, Haus P, Samlal S, Wong AC, Wood RJ, Petrucci V, Gunaratnam M, Hughes SM, Buluwela L, Turlais F, Neidle S, Meyer-Almes FJ, White AJ, Fuchter MJ.

J Med Chem. 2012 Feb 23;55(4):1731-50. doi: 10.1021/jm2016182. Epub 2012 Feb 9.

PMID:
22280363
23.

A simple laboratory practical to illustrate RNA mediated gene interference using drosophila cell culture.

Buluwela L, Kamalati T, Photiou A, Heathcote DA, Jones MD, Ali S.

Biochem Mol Biol Educ. 2010 Nov;38(6):393-9. doi: 10.1002/bmb.20437.

24.

Antiestrogens and their therapeutic applications in breast cancer and other diseases.

Ali S, Buluwela L, Coombes RC.

Annu Rev Med. 2011;62:217-32. doi: 10.1146/annurev-med-052209-100305. Review.

PMID:
21054173
25.

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.

Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PT, Lai CF, Al-Sabbagh M, Fisher RA, Barry S, Crnogorac-Jurcevic T, Martin LA, Dowsett M, Charles Coombes R, Kamalati T, Ali S, Buluwela L.

Breast Cancer Res Treat. 2011 Jul;128(2):357-68. doi: 10.1007/s10549-010-1122-6. Epub 2010 Aug 22.

PMID:
20730598
26.

The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells.

Thiruchelvam PT, Lai CF, Hua H, Thomas RS, Hurtado A, Hudson W, Bayly AR, Kyle FJ, Periyasamy M, Photiou A, Spivey AC, Ortlund EA, Whitby RJ, Carroll JS, Coombes RC, Buluwela L, Ali S.

Breast Cancer Res Treat. 2011 Jun;127(2):385-96. doi: 10.1007/s10549-010-0994-9. Epub 2010 Jul 6.

PMID:
20607599
27.

Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells.

Ngan S, Stronach EA, Photiou A, Waxman J, Ali S, Buluwela L.

Oncogene. 2009 May 14;28(19):2051-63. doi: 10.1038/onc.2009.68. Epub 2009 Apr 13.

PMID:
19363526
28.

Capsaicin-sensitive primary sensory neurons in the mouse express N-Acyl phosphatidylethanolamine phospholipase D.

Nagy B, Fedonidis C, Photiou A, Wahba J, Paule CC, Ma D, Buluwela L, Nagy I.

Neuroscience. 2009 Jun 30;161(2):572-7. doi: 10.1016/j.neuroscience.2009.03.047. Epub 2009 Mar 25.

29.

ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases.

Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, Jat P, Kindle KB, Heery DM, Parker MG, Buluwela L, Kamalati T, Ali S.

Nucleic Acids Res. 2006;34(21):6126-36. Epub 2006 Nov 3.

30.

T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif.

Lucey MJ, Chen D, Lopez-Garcia J, Hart SM, Phoenix F, Al-Jehani R, Alao JP, White R, Kindle KB, Losson R, Chambon P, Parker MG, Schär P, Heery DM, Buluwela L, Ali S.

Nucleic Acids Res. 2005 Nov 10;33(19):6393-404. Print 2005.

31.

Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-alpha and the transcriptional repressor PLZF.

Buluwela L, Pike J, Mazhar D, Kamalati T, Hart SM, Al-Jehani R, Yahaya H, Patel N, Sarwar N, Heathcote DA, Schwickerath O, Phoenix F, Hill R, Aboagye E, Shousha S, Waxman J, Lemoine NR, Zelent A, Coombes RC, Ali S.

Gene Ther. 2005 Mar;12(5):452-60. Erratum in: Gene Ther. 2005 Mar;12(6):552. Sarwarl, N [corrected to Sarwar, N]. Gene Ther. 2005 May;12(10):862.

PMID:
15647773
32.

Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.

Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DM.

Clin Cancer Res. 2004 Dec 1;10(23):8094-104.

33.

Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor.

Pike J, Holmes D, Kamalati T, Davies D, Tolhurst R, Mazhar D, Fishpool S, al-Jehani R, Waxman J, Zelent A, Lemoine NR, Ali S, Buluwela L.

Oncogene. 2004 Sep 30;23(45):7561-70.

PMID:
15334066
34.

Estrogen receptors and anti-estrogen therapies.

Buluwela L, Constantinidou D, Pike J, Ali S.

Cancer Treat Res. 2004;119:271-92. Review. No abstract available.

PMID:
15164882
35.

T:G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor alpha.

Chen D, Lucey MJ, Phoenix F, Lopez-Garcia J, Hart SM, Losson R, Buluwela L, Coombes RC, Chambon P, Schär P, Ali S.

J Biol Chem. 2003 Oct 3;278(40):38586-92. Epub 2003 Jul 21.

36.

Purified malignant mammary epithelial cells maintain hormone responsiveness in culture.

Kothari MS, Ali S, Buluwela L, Livni N, Shousha S, Sinnett HD, Vashisht R, Thorpe P, Van Noorden S, Coombes RC, Slade MJ.

Br J Cancer. 2003 Apr 7;88(7):1071-6.

37.

Expression of MUCI splice variants correlates with invasive growth of breast cancer cell lines.

Schmid BC, Buluwela L, Liu Q, Fasching B, Tong D, Stimpfl M, Andreas O, Leodolter S, Zeillinger R.

Breast Cancer Res Treat. 2002 Dec;76(3):211-9.

PMID:
12462382
38.

A vector with transcriptional terminators increases efficiency of cloning of an RNA virus by reverse transcription long polymerase chain reaction.

Cameron-Wilson CL, Zhang H, Zhang F, Buluwela L, Muir P, Archard LC.

J Mol Microbiol Biotechnol. 2002 Mar;4(2):127-31.

PMID:
11873908
39.

Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.

Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S.

Cancer Res. 2001 Mar 15;61(6):2782-7.

40.

Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.

Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, Weitzman SA, Korz D, Sukumar S.

Cancer Res. 2001 Feb 1;61(3):921-5.

41.
42.

Organization and conservation of the GART/SON/DONSON locus in mouse and human genomes.

Wynn SL, Fisher RA, Pagel C, Price M, Liu QY, Khan IM, Zammit P, Dadrah K, Mazrani W, Kessling A, Lee JS, Buluwela L.

Genomics. 2000 Aug 15;68(1):57-62.

PMID:
10950926
43.

HGF/SF in mammary epithelial growth and morphogenesis: in vitro and in vivo models.

Kamalati T, Niranjan B, Yant J, Buluwela L.

J Mammary Gland Biol Neoplasia. 1999 Jan;4(1):69-77. Review.

PMID:
10219907
44.

Endothelial cell transfection with cationic liposomes and herpes simplex-thymidine kinase mediated killing.

Fife K, Bower M, Cooper RG, Stewart L, Etheridge CJ, Coombes RC, Buluwela L, Miller AD.

Gene Ther. 1998 May;5(5):614-20.

45.

In vivo effects of hepatocyte growth factor/scatter factor on mouse mammary gland development.

Yant J, Buluwela L, Niranjan B, Gusterson B, Kamalati T.

Exp Cell Res. 1998 Jun 15;241(2):476-81.

PMID:
9637789
46.
47.

Expression of FGFR2 BEK and K-SAM mRNA variants in normal and malignant human breast.

Luqmani YA, Bansal GS, Mortimer C, Buluwela L, Coombes RC.

Eur J Cancer. 1996 Mar;32A(3):518-24.

PMID:
8814701
48.

Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells.

Liu QY, Niranjan B, Gomes P, Gomm JJ, Davies D, Coombes RC, Buluwela L.

Cancer Res. 1996 Mar 1;56(5):1155-63.

49.

A complete map of the human immunoglobulin VH locus.

Tomlinson IM, Cook GP, Walter G, Carter NP, Riethman H, Buluwela L, Rabbitts TH, Winter G.

Ann N Y Acad Sci. 1995 Sep 29;764:43-6. Review. No abstract available.

PMID:
7486559
50.

HGF/SF: a potent cytokine for mammary growth, morphogenesis and development.

Niranjan B, Buluwela L, Yant J, Perusinghe N, Atherton A, Phippard D, Dale T, Gusterson B, Kamalati T.

Development. 1995 Sep;121(9):2897-908.

Supplemental Content

Loading ...
Support Center